EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Thu, 27.03.2025
Berlin, 27 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) achieved a new record in the 2024 financial year with sales of € 295.8 million based on the preliminary annual financial statements*. Compared to the previous year, sales increased by almost € 50 million (+20%). EBIT before special items from continuing operations (adjusted ...
Berlin, DE & New York, USA, 25 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler’s high-purity Actinium-225 to further...
Berlin, DE & Hamilton, ON, CA, 20 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®) to support AtomVie’s CDMO activities f...
Berlin, Germany, 27 February 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), a leading provider of isotope technology for medical, scientific, and industrial use, today announced a comprehensive strategic partnership with Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeuti...
Berlin, 25 February 2025. Following a cyber-attack on the IT infrastructure of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) at the beginning of February, the Group's business operations can continue in most areas. In a few cases, there are still restrictions due to the gradual restoration at one point or another.
As of this week, all essent...
Berlin, 13 February 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) has suffered a cyber attack on parts of its IT systems. The systems were temporarily shut down proactively and disconnected from the internet to minimise any potential impact. The IT systems and the effects of the attack are currently being examined. The utmost care is be...
Press Release
IT Incident Affects Eckert & Ziegler SE's Communication Channels
Berlin, 03 February 2025. Due to an unexpected IT incident, Eckert & Ziegler is currently unable to receive emails or phone calls. We understand the inconvenience this may cause and want to assure our customers and partners that we are working diligently to ...
Financial Year 2024 (preliminary):
Sales of around EUR 295 million (previous year: EUR 246.1 million)
EBIT before special items of around EUR 66 million (previous year: EUR 46.9 million)
Net Income of around EUR 33 million (previous year: EUR 26.3 million)
Berlin, 27 January 2025. According to preliminary, unaudited figures, Eckert & Ziegle...
Berlin, 14 January 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi Kang Medical, Ltd (QKM), a joint venture between Eckert & Ziegler and the Chinese company DC Pharma, for the cyclotron technology used by Eckert & Ziegler to manufacture Ac-225. The contract guarantees Eckert & Ziegler a...
Berlin, Germany and Sydney, Australia, 13. January 2025. Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced the expansion of their existing Lutetium-177 based collaboration with a global s...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .